News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Angel Biotechnology Ltd to Sell Cramlington Facility, Concentrate Output at Pentlands
June 27, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Thomson Financial) - Angel Biotechnology Holdings PLC said, following the increased cost burden at its Cramlington facility near Newcastle, it has decided to close and sell it and concentrate production at its Pentlands, Edinburgh, facility.
Twitter
LinkedIn
Facebook
Email
Print
Real estate
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH INTELLIA THERAPEUTICS
The commercial launch playbook: Team structure, readiness and execution
June 15, 2026
·
6 min read
·
Jennifer C. Smith-Parker
Layoff Tracker
Genentech R&D cuts include longtime top exec
June 12, 2026
·
59 min read
·
BioSpace Editorial Staff
Manufacturing
FDA imposes import alert on Indian plant after inspectors flag GMP failings
June 12, 2026
·
2 min read
·
Nick Paul Taylor
Rare diseases
Amgen shores up Tavneos’ FDA defense with Duke data analysis
June 12, 2026
·
2 min read
·
Tristan Manalac